河南大学药学院导师谢松强简介 河大谢松强老师工作经历

考研导师的帮助不仅仅是在考研过程中，他们还能够帮助考生在职业发展中遇到困难时提供帮助和支持。一个好的考研导师能够成为考生一生的良师益友，为考生的人生道路提供有力的支持。天任考研小编已经整理好【河南大学药学院导师谢松强简介 河大谢松强老师工作经历】的内容，一起来看看吧！

1.个人信息（Personals）：
男，1973年11月生，博士，教授，博士生导师，河南大学****。国家食品药品监督管理局化妆品审评专家，国家自然科学基金通信评审专家。河南省药理学会副理事长，河南省高校科技创新型团队“抗肿瘤药物药理”带头人，河南省教育厅学术技术带头人。Email：xiesq@vip.henu.edu.cn
2.受教育经历 (Educational Experience) ：
2005/09-2008/07，沈阳药科大学，药理学，博士生
2000/09-2003/07，郑州大学，药理学，硕士生
1994/09-1997/07，开封医学高等专科学校，药学。
3.工作经历(Professional Experience) ：
2012/12–至今，河南大学，药学院，教授；
2008/11–2012/11，河南大学，药学院，副教授；
2003/11–2008/10，河南大学，药学院，讲师。
4. 研究兴趣（Research Interests）：肿瘤药理学。
5. 承担项目情况(Financial Supports)
[1] 基于EGFR介导的β-catenin浆核穿梭研究AKT1对乳腺癌转移的负性调控（项目号**），国家自然科学基金面上项目，53万元，起讫时间2018.01-2021.12，主持人。
[2] 多胺微环境对DKK1功能及肝癌、乳腺癌转移性能的影响（项目号**），国家自然科学基金面上项目，54万元，起讫时间2016.01-2019.12，主持人。
[3] 多胺与肿瘤的抗肿瘤药物药理研究（项目号19IRTSTHN004），河南省高校科技创新团队支持计划，100万元，起讫时间2019.01-2020.12，主持人
[4] 多胺微环境对肝癌细胞转移性能及AKT功能的影响（项目号U**），国家自然科学基金-河南省联合基金，30万，起讫时间 2013.01-2015.12，主持人。
[5] 多胺与肝癌转移（项目号14HASTIT033），河南省高校科技创新人才支持计划，60万，起讫时间2014.01-2016.12，主持人。
6. 近3年代表性论文(Journal Articles) ：
[1] Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo.
Bi S, Wei Q, Zhao Z, Chen L, Wang C, Xie S. Front Pharmacol. 2019 Aug 2;10:864. doi: 10.3389/fphar.2019.00864. eCollection 2019.
[2] DKK1 inhibits breast cancer cell migration and invasion through suppression of β-catenin/MMP7 signaling pathway.
Niu J, Li XM, Wang X, Liang C, Zhang YD, Li HY, Liu FY, Sun H, Xie SQ, Fang D. Cancer Cell Int. 2019 Jun 24;19:168. doi: 10.1186/s12935-019-0883-1. eCollection 2019.
[3] Elucidation of the Differences in Cinobufotalin's Pharmacokinetics Between Normal and Diethylnitrosamine-Injured Rats: The Role of P-Glycoprotein.
Zhang X, Liu T, Zhang Y, Liu F, Li H, Fang D, Wang C, Sun H, Xie S.
Front Pharmacol. 2019 May 17;10:521. doi: 10.3389/fphar.2019.00521. eCollection 2019.
[4] Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Niu J, Wang X, Liang C, Zhang YD, Liu FY, Li HY, Xie SQ, Sun H, Fang D.
Cell Biol Int. 2019 Aug;43(8):931-939. doi: 10.1002/cbin.11183. Epub 2019 Jun 18.
[5] Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
Chen L, Bi S, Hou J, Zhao Z, Wang C, Xie S. Cell Commun Signal. 2019 Apr 11;17(1):31. doi: 10.1186/s12964-019-0343-5.
[6] Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy.
Hou JZ, Xi ZQ, Niu J, Li W, Wang X, Liang C, Sun H, Fang D, Xie SQ. Oncol Rep. 2019 Mar;41(3):1971-1979. doi: 10.3892/or.2018.6928. Epub 2018 Dec 12.
[7] Uridine diphosphate release mechanism in O-N-acetylglucosamine (O-GlcNAc) transferase catalysis.
She N, Zhao Y, Hao J, Xie S, Wang C. Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):609-622. doi: 10.1016/j.bbagen.2018.12.005. Epub 2018 Dec 11.
[8] Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
Li W, Hou JZ, Niu J, Xi ZQ, Ma C, Sun H, Wang CJ, Fang D, Li Q, Xie SQ.
Cell Commun Signal. 2018 Nov 16;16(1):82. doi: 10.1186/s12964-018-0295-1.
[9] Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo.
Ma J, Liu H, Xi Z, Hou J, Li Y, Niu J, Liu T, Bi S, Wang X, Wang C, Wang J, Xie S, Wang PG. Front Chem. 2018 Sep 21;6:386. doi: 10.3389/fchem.2018.00386. eCollection 2018.
[10] Sulfation disposition of liquiritigenin in SULT1A3 overexpressing HEK293 cells: The role of breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 4 (MRP4) in sulfate efflux of liquiritigenin.
Liu T, Zhang X, Zhang Y, Hou J, Fang D, Sun H, Li Q, Xie S. Eur J Pharm Sci. 2018 Nov 1;124:228-239. doi: 10.1016/j.ejps.2018.08.041. Epub 2018 Aug 31.
[11] Synthesis and biological evaluation of novel asymmetric naphthalene diimide derivatives as anticancer agents depending on ROS generation.
Xu X, Wang S, Chang Y, Ge C, Li X, Feng Y, Xie S, Wang C, Dai F, Luo W.
Medchemcomm. 2018 Jul 6;9(8):1377-1385. doi: 10.1039/c8md00265g. eCollection 2018 Aug 1.
[12] Discovery of the Polyamine Conjugate with Benzo[ cd]indol-2(1 H)-one as a Lysosome-Targeted Antimetastatic Agent.
Li J, Tian R, Ge C, Chen Y, Liu X, Wang Y, Yang Y, Luo W, Dai F, Wang S, Chen S, Xie S, Wang C. J Med Chem. 2018 Aug 9;61(15):6814-6829. doi: 10.1021/acs.jmedchem.8b00694. Epub 2018 Jul 23.
[13] Sensitization of TRPV1 receptors by TNF-α orchestrates the development of vincristine-induced pain.
Wang Y, Feng C, He H, He J, Wang J, Li X, Wang S, Li W, Hou J, Liu T, Fang D, Xie SQ. Oncol Lett. 2018 Apr;15(4):5013-5019. doi: 10.3892/ol.2018.7986. Epub 2018 Feb 7.
[14] The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
Li Q, Zhu ZX, Zhang X, Luo W, Chang LP, Chen S, Wang YX, Xie SQ, Chang CC, Wang CJ. Eur J Med Chem. 2018 Feb 25;146:564-576. doi: 10.1016/j.ejmech.2018.01.074. Epub 2018 Jan 31.
[15] Synthesis and biological evaluation of naphthalimide-polyamine conjugates modified by alkylation as anticancer agents through p53 pathway.
Dai F, He H, Xu X, Chen S, Wang C, Feng C, Tian Z, Dong H, Xie S. Bioorg Chem. 2018 Apr;77:16-24. doi: 10.1016/j.bioorg.2017.12.036. Epub 2018 Jan 4.
[16] Synthesis and biological evaluation of novel alkylated polyamine analogues as potential anticancer agents.
Li M, Wang Y, Ge C, Chang L, Wang C, Tian Z, Wang S, Dai F, Zhao L, Xie S.
Eur J Med Chem. 2018 Jan 1;143:1732-1743. doi: 10.1016/j.ejmech.2017.10.069.
[17] MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation.
Zhao Y, Ge CC, Wang J, Wu XX, Li XM, Li W, Wang SS, Liu T, Hou JZ, Sun H, Fang D, Xie SQ. Oncol Rep. 2017 Nov;38(5):3055-3063. doi: 10.3892/or.2017.5955. Epub 2017 Sep 13.
[18] Design, Synthesis and Evaluation of Naphthalimide Derivatives as Potential Anticancer Agents for Hepatocellular Carcinoma.
Ge C, Chang L, Zhao Y, Chang C, Xu X, He H, Wang Y, Dai F, Xie S, Wang C.
Molecules. 2017 Feb 22;22(2). pii: E342. doi: 10.3390/molecules**.
[19] Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity.
Dai F, Li Q, Wang Y, Ge C, Feng C, Xie S, He H, Xu X, Wang C.
J Med Chem. 2017 Mar 9;60(5):2071-2083. doi: 10.1021/acs.jmedchem.6b01846. Epub 2017 Feb 21.
[20] Extracellular polyamines-induced proliferation and migration of cancer cells by ODC, SSAT, and Akt1-mediated pathway.
Dai F, Yu W, Song J, Li Q, Wang C, Xie S. Anticancer Drugs. 2017 Apr;28(4):457-464. doi: 10.1097/CAD.0465.
[21] Synthesis and Biological Evaluation of Novel Aromatic Imide-Polyamine Conjugates.
Li M, Wang Y, Zhang J, Xie S, Wang C, Wu Y. Molecules. 2016 Nov 30;21(12). pii: E1637.
[22] Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells.
Wang C, Ruan P, Zhao Y, Li X, Wang J, Wu X, Liu T, Wang S, Hou J, Li W, Li Q, Li J, Dai F, Fang D, Wang C, Xie S. Oncotarget. 2017 Jan 3;8(1):1092-1109. doi: 10.18632/oncotarget.13582.
[23]Synthesis and evaluation of novel amonafide-polyamine conjugates as anticancer agents.
Wang Y, Zhang J, Li M, Li M, Xie S, Wang C. Chem Biol Drug Des. 2017 May;89(5):670-680. doi: 10.1111/cbdd.12888. Epub 2016 Nov 19.
7.奖励（Awards）：
[1]谢松强，王超杰，王玉霞，陈亮，李骞，张亚宏，田智勇. 多胺与肿瘤。河南省人民政府，河南省科技进步奖，三等奖，2018年.
[1]王超杰，谢松强，王建红，田智勇，程鹏飞，李骞，赵瑾. 靶向性多胺缀合物抗肿瘤作用及机制研究。河南省人民政府，河南省科技进步奖，三等奖，2013年.

以上是天任考研为考生整理【河南大学药学院导师谢松强简介 河大谢松强老师工作经历】的相关信息，考生在备考过程中想要了解【报名要求，考试大纲，院校排名，热门专业，报考人数，职业规划，免费电子版复习资料，复试调剂】，可以在右侧窗口留言，会有老师一对一为大家答疑解惑，助力各位考生顺利进入理想院校。